tirzepatide and gallstones Does Cause Gallstones? Risks Prevention Guide GLP-1 receptor agonists and gallbladder

[ At our Plymouth clinic, we look for specific clinical markers before discussing any taper: Sustained target weight reached and maintained for a minimum of three to six months Stable fasting glucose and HbA1c at goal if applicable No active comorbidities being driven by unmanaged obesity Demonstrated behavioral patterns consistent nutrition, physical activity, and stress management that are likely to persist off medication When these criteria are met, a supervised weaning conversation begins

SURMOUNT-3 tested a different question: can tirzepatide maintain and extend weight loss achieved through an initial intensive lifestyle intervention

Weeks 5-8: Acceleration Phase As Tirzepatide dose increases to 5mg and then 7.5mg, appetite suppression becomes more pronounced

That is the principal reason procurement teams specify tirzepatide rather than a GLP-1-only reference peptide